Yanyin Technology

What Yanyin Technology does

Yanyin Technology (上海衍因科技有限公司) is a Shanghai-based, privately held life-sciences software company founded in October 2023 that builds an AI-powered biomedical digital scientific research collaboration platform. Its flagship product suite comprises yanCloud (衍因智研云) — integrating a molecular cloning workbench (yanMolecule), electronic lab notebook (yanNote), LIMS (yanLIMS), AI literature management (yanLibrary), and research data management (yanData) — and yanAgent (衍因灵研智能体), a family of AI agents for literature interpretation, CRISPR design, compliance review, IND application generation, and customer service. The platform targets three customer segments: innovative pharmaceutical and biotech companies (80+ served) for regulated R&D digitization, universities and research institutions (430+ served) via a free academic tier, and hospitals and medical research institutes (280+ served), with solution packages specialized for gene therapy, cell therapy, antibody drugs, and synthetic biology.

Underlying the product is the AI MEGASphere platform, which combines a compliance module (audit trails, role-based access, approval workflows aligned with FDA 21 CFR Part 11 and China GMP), a data platform, an open API/webhook layer, and an intelligent computing layer for model training and deployment. Yanyin operates a tiered SaaS revenue model: a free academic version drives user acquisition and brand awareness, paid professional subscriptions monetize individual researchers, and quote-based annual enterprise contracts serve pharma and large institutions; the company also earns through co-marketing partnerships such as the joint hardware-software high-throughput synthesis solution with XinSu Tech (芯宿科技).

The company is led by CEO and founder Chen Zeping (陈泽平), formerly VP/GM at Taimei Medical Technology and SAP Greater China, and co-founder/CTO Shi Huihui (史辉辉), previously at SAP and ConvertLab. It is backed by Qiming Venture Partners via a tens-of-millions-of-RMB angel round in March 2024, holds ISO 9001/27001/20000 and Cybersecurity Level Protection Level 3 certifications, and has been recognized in NVIDIA's 2025 startup showcase, iFlytek's AI Developer Competition, and CAICT's Digital Medical Atlas. Yanyin is currently 11–50 employees and operates exclusively in the China market.

Name

Yanyin Technology

Legal name

上海衍因科技有限公司

Website

https://yanyin.tech

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Yanyin Technology (衍因科技) is a Shanghai-based AI SaaS company that builds yanCloud, an integrated biomedical research collaboration platform combining molecular biology tools, electronic lab notebooks, LIMS, and AI agents, serving pharma companies, universities, and hospitals across China.

Ownership category

akta.pro rank

Product category

Biomedical Research Collaboration Software

NAICS

Computer Systems Design Services (541512), Custom Computer Programming Services (541511), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518210)

SIC

Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

akta.pro secondary industries

Model Development & Training Platforms (AutoML, Notebooks, Feature Stores) (HDAEANAB), Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN), Enterprise Foundation Model Integration & APIs (Connectors, Governance, Deployment) (HDAAACAO)

Keywords

• Biomedical research software
• Electronic lab notebook
• Molecular biology tools
• AI drug discovery
• Scientific data management

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. SaaS Subscription (Enterprise & Professional): Tiered SaaS subscription model with free academic version, paid professional version for individual researchers, and paid enterprise version for biotech companies and large institutions. Revenue generated through annual or multi-year subscription licenses.
2. Freemium Academic Tier: Free academic version for university researchers and students drives user adoption and community building, with conversion pathway to paid professional/enterprise tiers.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Yanyin Technology builds and sells yanCloud, an AI-powered biomedical digital scientific research collaboration SaaS platform that combines a molecular cloning workbench (yanMolecule), an electronic lab notebook (yanNote), a laboratory information management system (yanLIMS), and AI literature management (yanLibrary) with a family of biomedical AI agents (yanAgent). The platform is offered in a free Academic tier for universities, a paid Professional tier for individual researchers, and a quote-based Enterprise tier for biotech companies and large institutions, with the AI MEGASphere platform providing compliance, data, open APIs, and intelligent computing infrastructure underneath.

Differentiator

Problem solved

Functional benefit

Brands

• 衍因智研云 (yanCloud): AI-powered biomedical digital scientific research collaboration platform featuring molecular biology tools, electronic lab notebooks, research data management, and literature tools
• 衍因灵研智能体 (yanAgent)
• AI MEGASphere平台
• 智研分子 (yanMolecule)
• 智研笔记 (yanNote)
• 智研实验 (yanLIMS)
• 智研文献 (yanLibrary)

Products and services

• yanCloud (衍因智研云) — AI Biomedical Digital Scientific Research Collaboration Platform Enterprise-grade SaaS collaboration platform for biomedical research that integrates molecular biology tools, electronic lab notebook, LIMS, literature management, and AI agents in a single multi-tenant environment with compliance, audit, and permission controls. Used by biotech companies, universities, and research hospitals.
• yanMolecule (智研分子) — Molecular Biology Workbench Professional molecular biology tool supporting sequence visualization and editing, plasmid construction, primer design, and molecular cloning workflows. Used by biomedical researchers and gene/cell therapy R&D teams.
• yanNote (智研笔记) — Electronic Lab Notebook Digital electronic lab notebook for collaborative research data management and recording with free editing, structured editing, template library, and experiment plugins. Used by academic labs and biotech R&D teams needing compliant experiment records.
• yanLIMS (智研实验) — Laboratory Information Management System Laboratory information management system for sample management, material/inventory management, equipment management, and inspection request workflows. Used by biotech labs and hospital research departments to track samples, reagents, and equipment.
• yanLibrary (智研文献) — AI Literature Management Platform

Quantifiable outcome

• Served 80+ innovative pharma companies, 280+ research institutions and hospitals, and 430+ universities and colleges
• +3 more outcomes

Named customers35 records

Segments7 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

Partnerships

18 partnerships are on record, tiered major, core and minor.

• 神拓生物majorStrategic or Co-development Partner · 12 January 2026Strategic partnership to build a virtual cell platform for in-vivo gene therapy R&D, leveraging各自优势共同推动基因治疗领域的技术创新。
• 上技所数字科技 & 芯超数据 (Shanghai Tech Exchange & XinChao Data)majorStrategic or Co-development Partner · 15 September 2025Three-party strategic cooperation integrating AI capabilities, national-level data resources, and biomedical fields to build a health data cooperation ecosystem and promote digital transformation.
• 东阳光药业coreStrategic or Co-development Partner · 11 September 2025AI R&D agent partnership for drug globalization. Yanyin developed AI translation platform for IND filing and is collaborating on AI lab automation robot scenarios to support East Sunshine's global expansion strategy.
• 上海宝山合成生物学转化研究院minorStrategic or Co-development Partner · 9 September 2025Jointly developed free AI cell counting mini-program 'Cell Spot' with zero-cost cell counting capability and cell confluence analysis for cell culture researchers.
• 益杰立科 (EpiGen)majorStrategic or Co-development Partner · 7 September 2025Digitization partnership using YanYan Intelligent Research Cloud ELN and material inventory management modules to enhance R&D efficiency and data management in epigenetic gene regulation therapy.
• 环码生物 (Circode Bio)coreStrategic or Co-development Partner · 2 September 2025Three-year strategic partnership to explore deep AI agent applications in novel circular RNA drug R&D, building an intelligent R&D new paradigm.
• 篆码生物majorTechnology or Integration · 27 November 2024Strategic partnership to jointly promote CRISPR gene editing module software R&D and market expansion. Combining各自在基因编辑领域的专长。
• 洛启生物majorStrategic or Co-development Partner · 14 October 2024Strategic partnership integrating各自在生物医药领域的先进技术及专业知识，提升加速纳米抗体创新药物的研发进程。Yanyin provides its digital platform for Luoqi's nanobody drug R&D.
• 邦耀生物 (BioRay)majorStrategic or Co-development Partner · 25 September 2024Partnership combining AI scientific services with gene and cell therapy expertise to jointly accelerate gene and cell therapy R&D and industrialization.
• 演生潮majorStrategic or Co-development Partner · 24 September 2024Strategic partnership leveraging各自在人工智能科研服务和获得性免疫失调新靶点药物研发方面的优势，共同推动生物医药科研领域的创新与发展。
• 泓迅生物 (Syngend Bio)majorStrategic or Co-development Partner · 26 August 2024Comprehensive strategic partnership in synthetic biology, providing closed-loop services from primer design/synthesis, plasmid design/construction, gene synthesis, and sequencing to editing for synthetic biology customers.
• 元动生物majorStrategic or Co-development Partner · 20 August 2024Strategic partnership to empower high-performance bio-based material innovation. Yanyin's platform accelerates YuanDong Bio's R&D workflows, particularly in nanocellulose production and biomaterial development.
• 惠思乐健康科技minorStrategic or Co-development Partner · 13 August 2024Strategic partnership to jointly promote biotech innovation in beauty and health sector, combining Yanyin's digital platform with HuIsile's synthetic biology technology.
• 晟迪生物minorStrategic or Co-development Partner · 7 August 2024Strategic cooperation to expand biotech application areas. Shengdi's LNP technology combined with Yanyin's AI model and digital platform to accelerate drug R&D efficiency and quality.
• 深势科技 (DeepPotential Technology)majorStrategic or Co-development Partner · 26 April 2024Joint AI biomedical model R&D partnership to build 'AI-driven biomedical R&D joint solution', combining DeepPotential's AI for Science capabilities with Yanyin's digital research platform.
• 芯宿科技 (XinSu Tech)coreStrategic or Co-development Partner · 22 April 2024Jointly released China's first high-throughput synthesis hardware-software integrated solution. Yanyin provides yanMolecule and yanNote modules while XinSu provides its CMOS-based high-throughput synthesis platform for integrated DNA synthesis solutions.
• 爱信智耀 (Ailomics Therapeutics)majorStrategic or Co-development Partner · 19 April 2024Deep partnership where Ailomics uses yanMolecule for managing antibody sequences, plasmid construction, and molecular cloning across multiple projects to accelerate antibody drug R&D.
• 张江集团majorStrategic or Co-development Partner · 26 January 2024Co-hosted '智能驱动 共享未来——2024年度生物医药智享会' and jointly released '生物医药研在线公共服务平台' to serve Zhangjiang biotech companies.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• IDBS (Danaher): IDBS provides scientific informatics platforms including ELN and data management for biopharma R&D. Overlaps with Yanyin's yanCloud in electronic lab notebooks and research data management for drug discovery.
• Dotmatics: Dotmatics (now part of Siemens) provides scientific intelligence and ELN/LIMS software for drug discovery and development. Comparable in target market (biopharma R&D) and ELN functionality, with broader cheminformatics and data analytics portfolio.
• Benchling: Benchling is the leading cloud-based life sciences R&D platform offering ELN, LIMS, molecular biology, and inventory management. Directly competes with Yanyin's yanCloud in biomedical research collaboration, with broader global footprint and larger customer base among top-20 pharma.
• LabVantage Solutions: LabVantage is an enterprise LIMS provider serving pharmaceutical, biotech, and research organisations. Competes with Yanyin's yanLIMS module in sample/material/equipment management and lab workflow digitisation.

Emerging players

• Zhipu AI: Zhipu AI is a Chinese foundation model company developing GLM models with applications in life sciences. Comparable as a Chinese AI platform player but more general-purpose; Yanyin specialises the foundation model layer for biomedical R&D workflows.
• Schrödinger: Schrödinger provides AI-based computational chemistry and drug discovery platform. Comparable in applying AI/ML to biomedical R&D, though more focused on molecular simulation and computational chemistry than lab workflow digitisation.
• DeepPotential Technology: DeepPotential Technology is Yanyin's strategic AI partner for 'AI for Science' biomedical R&D solutions. Comparable in applying AI foundation models to scientific research, with partial overlap in AI biomedical capabilities.

Broad incumbents

• Revvity Signals: Revvity Signals (formerly PerkinElmer Informatics) offers enterprise scientific software including ELN, LIMS, and data analytics for life sciences. Larger incumbent with broader portfolio including instruments, reagents, and software serving similar pharma/biotech customers.

Others

• SAPA-China: SAPA-China is a Chinese-American Pharmaceutical Professionals Association that serves as both an industry network Yanyin engages with and a marketing channel. Ecosystem/partner relationship rather than direct competitor, but operates in the same target customer base.
• ConvertLab: ConvertLab is a marketing technology platform where Yanyin's co-founder/CTO Shi Huihui previously served as R&D Director. Not a direct competitor but a connected ecosystem company through talent and Chinese enterprise SaaS experience.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/yanyin

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yanyin Technology